Webinar: Evaluation of Checkpoint Inhibitor Therapies using a Mixed Lymphocyte Reaction (MLR) Assay

Immune checkpoints are signaling molecules which control the synapse between T cells and antigen presenting cells (APCs).

Checkpoint inhibitor therapies target and inhibit the signals that ‘switch off’ T cells, leading to an upregulation of T cell activation and tumor cell killing.

The mixed lymphocyte reaction (MLR) mimics the T cell and APC synapse by co-culturing immune cells from two individuals. MLR is used as a model, to explore the effects of checkpoint inhibitor drugs in vitro; facilitating biological research applications and drug discovery processes.
 

Key webinar discussion topics include:

  • The impact of checkpoint inhibitor therapeutics on inflammatory cytokine release
  • How the iQue® Advanced Flow Cytometry Platform and associated reagent kits can be used to quantify T cell response in MLR
  • The use of the iQue® MLR assay to generate pharmacological outputs for checkpoint inhibitor induced T cell activation

Complete the Form Below to Download the Webinar

About the speaker


Kirsty McBain
Associate Scientist
iQue® Applications Group, Sartorius

Kirsty McBain is an Associate Scientist in the iQue® Applications Group, part of the European based BioAnalytics at Sartorius, where she is involved in the research and development of novel applications.

Kirsty’s efforts are focused on the iQue® 3 advanced flow cytometry platform where she has supported a number of the immuno-oncology campaigns that are used to exemplify how Sartorius technology can be applied to the drug discovery process. Kirsty obtained a master’s degree in Biochemistry at the University of Bristol before joining Sartorius in 2019.

Request More Information

What other areas are you interested in? (select all that apply)

Register to watch the on-demand webinar